Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II Open Label, Multi-arm, Parallel Cohort Dose Finding and Expansion Study to Assess the Safety, Pharmacokinetics and Efficacy of NUC-3373, a Nucleotide Analogue, Given in Combination With Standard Approved Agents in Patients With Advanced Solid Tumours

NCT05714553 is registered in ClinicalTrials.gov with NuCana plc as lead sponsor.

NCT NCT05714553
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05714553 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II Open Label, Multi-arm, Parallel Cohort Dose Finding and Expansion Study to Assess the Safety, Pharmacokinetics and Efficacy of NUC-3373, a Nucleotide Analogue, Given in Combination With Standard Approved Agents in Patients With Advanced Solid Tumours
Lead sponsor
NuCana plc
Phase
Phase 1/2
Overall status
Terminated
Start date
March 8, 2023
Completion date
May 30, 2025
Enrollment
19 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, advanced solid tumor, classical hodgkin lymphoma, endometrial carcinoma, gastric cancer, head and neck squamous cell carcinoma, melanoma, metastatic cancer, msi-h colorectal cancer, neoplasm malignant, non small cell lung cancer, oesophageal carcinoma, pleural mesothelioma, renal cell carcinoma, subungual squamous cell carcinoma, triple negative breast cancer, urothelial carcinoma